Document:

eWELLNESS
HEALTHCARE CORPORATION AND

AKASH BAJAJ M.D., M.P.H. MEDICAL ADVISORY 

AGREEMENT

 

 

 

    	 

    	 

    

 

eWELLNESS HEALTHCARE CORPORATION AND AKASH
BAJAJ M.D., M.P.H. MEDICAL ADVISORY AGREEMENT

 

THIS MEDICAL ADVISORY AGREEMENT (one-year)
is made and entered into effective April 17, 2015, by and among: eWellness Healthcare Corporation (hereinafter “the Company”
and or “EHC”) and Akash Bajaj M.D., M.P.H. (Hereinafter “Advisor”).

 

INTRODUCTION

 

1. The Company desires to have the benefit
of the Advisors’ knowledge and experience in the development of its telemedicine technology (“PHZIO.COM”), and
the Advisor desires to provide consulting services to the Company, all as provided in this Agreement.

 

2. The Company desires to have the Advisor
serve as a Chairman of the Company’s Clinical Advisory Board (the “CAB”), and the Advisor desires to serve as
a Chairman of the CAB.

 

NOW, THEREFORE, in consideration of the promises
and mutual agreements set forth in this Agreement, the Company and the Advisor agree as follows:

 

1. Consultation and Clinical Advisory Board.
The Company shall retain the Advisor as a consultant, and the Advisor shall serve the Company as a consultant and a member of the
CAB upon the terms and conditions set forth in this Agreement. However, the Advisor shall be engaged by the Company as a consultant
for the exchange of ideas only and shall not direct or conduct research for or on behalf of the Company. The Company and the Advisor
acknowledge that the CAB is not a committee of the Company’s Board of Directors.

 

2. Term. Subject to the terms and conditions
set forth in Section 5 below, the term of the Advisor’s consulting arrangement and service on the CAB (hereinafter referred
to as the “Consultation Period”) shall commence on the Effective Date and shall continue until the first anniversary
of the Effective Date, unless extended by mutual agreement for additional one year periods.

 

3. Consulting and CAB Duties.

3.1. During the Consultation Period, Advisor
shall serve as Chairman of the CAB and shall provide to the Company such consulting services in his fields of expertise and knowledge
related to co-drafting and co-publishing at least one 6-month clinical study of at least 100 patients that participate in the
Company’s PHZIO.COM exercise program (the “Services”), through Evolution Physical Therapy, Inc. (Hereinafter
“EPT”), which is anticipated to including providing at least the equivalent of four (4) eight hour days of CAB service
per year. The data to be analyzed for the clinical study will be provided to the Advisor by EPT. The Company shall give the Advisor
reasonable advance notice of any Services required of him hereunder. The number and frequency of meetings of the CAB to be held
during the Consultation Period shall be determined at the consent of both the Advisor and the Company.

 

    	2

    	 

    

 

3.2. The Advisor shall devote his best efforts
and ability to the performance of the duties attaching to this obligation. All work performed by the Advisor for the Company shall
be at times reasonably convenient to the Advisor.

 

4. Compensation.

4.1. Consulting Fees. The Company shall
pay to the Advisor consulting fees of US$255.00 per hour for services performed, payable in arrears on the last day of the month
following the month in which services were rendered. Advisor shall calculate Consulting Fees for services performed outside formal
CAB meetings on a pro rata basis and shall invoice Company for fees owed to Advisor under this Section 4.1. The hourly rate
was calculated from data located at www.salary.com for leading (top in their field) pain management physicians located in Los
Angeles, California, as Dr. Bajaj is a double Board Certified physician we deemed him to be a leading top in the field physician.

 

4.2. Stock Options. Subject to the approval
of the Board of Directors, the Company shall grant the Advisor a 5-year non-statutory option (the “Option”) to purchase
one hundred thousand (100,000) shares of the Company’s common stock, $0.001 par value per share (“Common Stock”),
at a price of $0.35 per share. The stock option will vest over a 12-month period at 8,333 shares per month. As the Company’s
common stock is currently not publically traded, thus the value of these options are deemed to be $0.00 in current value.

 

4.3. Reimbursement of Expenses. The
Company shall reimburse the Advisor for all reasonable and necessary expenses incurred or paid by the Advisor in connection with,
or related to, the performance of his services under this Agreement. The Advisor shall submit to the Company itemized statements,
in a form satisfactory to the Company, of such expenses incurred by the Advisor. The Company shall pay to the Advisor the amounts
shown on each such statement within 30 days after receipt thereof. Notwithstanding the foregoing, the Advisor shall not incur total
expenses in excess of US$500 per month without the prior written approval of the Company.

 

4.4. Benefits. The Advisor shall not
be entitled to any benefits, coverages or privileges, including, without limitation, social security, unemployment, medical or
pension payments, made available to employees of the Company.

 

    	3

    	 

    

 

5. Termination. Either party may terminate
the Consultation Period upon thirty (30) days prior written notice to the other party. The Consultation Period shall also
terminate automatically upon the death or disability of the Advisor. In the event of any such termination, the Advisor shall be
entitled to payment for services performed and expenses paid or incurred prior to the effective date of termination, subject to
the limitation on reimbursement of expenses set forth in Section 4.3. Such payments shall constitute full settlement of any
and all claims of the Advisor of every description against the Company, other than the Advisor’s right to indemnification
under Section 10 of this Agreement. In addition, any shares of restricted Common Stock issued pursuant to the Restricted Stock
Agreement which have not vested as of the date of termination shall be purchasable by the Company in accordance with the provisions
set forth in the Restricted Stock Agreement. Notwithstanding the foregoing, the Company may terminate the Consultation Period,
effective immediately upon receipt of written notice, if the Advisor breaches or threatens to breach any provision of Section 6,
7, or 9. The following provisions shall survive termination of this Agreement: Sections 7, 9, 10 and 14.

 

6. Cooperation. The Advisor shall use
his best efforts in the performance of his obligations under this Agreement. The Company shall provide such access to its information
and property as may be reasonably required in order to permit the Advisor to perform his obligations hereunder. The Advisor shall
cooperate with the Company’s personnel, shall not interfere with the conduct of the Company’s business and shall observe
all rules, regulations and security requirements of the Company concerning the safety of persons and property.

 

7. Non-Disclosure and Developments.

7.1. Proprietary Information. 

(a) The Advisor agrees that all information,
whether or not in writing, of a private, secret or confidential nature concerning the Company’s business, business relationships
or financial affairs (collectively, “Proprietary Information”) is and shall be the exclusive property of the Company.
By way of illustration, but not limitation, Proprietary Information may include inventions, products, processes, methods, techniques,
formulas, compositions, compounds, projects, developments, plans, research data, clinical data, financial data, personnel data,
computer programs, customer and supplier lists, and contacts at or knowledge of customers or prospective customers of the Company.
The Advisor will not disclose any Proprietary Information to any person or entity other than employees of the Company or use the
same for any purposes (other than in the performance of his duties as an employee of the Company) without written approval by an
officer of the Company, either during or after the Consultation Period, unless and until such Proprietary Information has become
public knowledge without fault by the Advisor. The Advisor agrees that all files, letters, memoranda, reports, records, data, sketches,
drawings, laboratory notebooks, program listings, or other written, photographic, or other tangible material containing Proprietary
Information, whether created by the Advisor or others, which shall come into his custody or possession, shall be and are the exclusive
property of the Company to be used by the Advisor only in the performance of his duties for the Company. All such materials or
copies thereof and all tangible property of the Company in the custody or possession of the Advisor shall be delivered to the Company,
upon the earlier of (i) a request by the Company or (ii) termination of this Agreement. After such delivery, the Advisor
shall not retain any such materials or copies thereof or any such tangible property.

 

    	4

    	 

    

 

(b) The Advisor agrees that his/her obligation
not to disclose or to use information and materials of the types set forth in paragraphs (a) and (b) above, and his obligation
to return materials and tangible property, set forth in paragraph (b) above, also extends to such types of information, materials
and tangible property of customers of the Company or suppliers to the Company or other third parties who may have disclosed or
entrusted the same to the Company or to the Advisor.

 

7.2. Developments.

(a) The Advisor will make full and prompt
disclosure to the Company of all inventions, improvements, discoveries, methods, developments, software, and works of authorship,
whether patentable or not, which are created, made, conceived or reduced to practice by him/her or under his/her direction or
jointly with others during the Consultation Period, whether or not during normal working hours or on the premises of the Company,
which relate directly or indirectly, to the business of the Company AND arise out of Advisor’s consulting relationship with
the Company (all of which are collectively referred to in this Agreement as “Developments”).

 

(b) The Advisor agrees to assign and does hereby
assign to the Company (or any person or entity designated by the Company) all his right, title and interest in and to all Developments
and all related patents, patent applications, copyrights and copyright applications. However, this paragraph 7.2(b) shall not apply
to Developments which do not relate to the present or planned business or research and development of the Company and which are
made and conceived by the Advisor not during normal working hours, not on the Company’s premises and not using the Company’s
tools, devices, equipment or Proprietary Information. The Advisor understands that, to the extent this Agreement shall be construed
in accordance with the laws of any state which precludes a requirement in an employee agreement to assign certain classes of inventions
made by an employee, this paragraph 7.2(b) shall be interpreted not to apply to any invention which a court rules and/or the Company
agrees falls within such classes. The Advisor also hereby waives all claims to moral rights in any Developments.

 

(c) The Advisor agrees to cooperate fully with
the Company, both during and after the Consultation Period, with respect to the procurement, maintenance and enforcement of copyrights,
patents and other intellectual property rights (both in the United States and foreign countries) relating to Developments. The
Advisor shall sign all papers, including, without limitation, copyright applications, patent applications, declarations, oaths,
formal assignments, assignments of priority rights, and powers of attorney, which the Company may deem necessary or desirable in
order to protect its rights and interests in any Development. The Advisor further agrees that if the Company is unable, after reasonable
effort, to secure the signature of the Advisor on any such papers, any executive officer of the Company shall be entitled to execute
any such papers as the agent and the attorney-in-fact of the Advisor, and the Advisor hereby irrevocably designates and appoints
each executive officer of the Company as his agent and attorney-in-fact to execute any such papers on his behalf, and to take any
and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any Development,
under the conditions described in this sentence.

 

    	5

    	 

    

 

7.3. Other Agreements. The Advisor hereby
represents that the Advisor is not bound by the terms of any agreement with any previous or current employer or other party to
refrain from using or disclosing any trade secret or confidential or proprietary information in the course of the Consultation
Period, to refrain from competing, directly or indirectly, with the business of such previous or current employer or any other
party or to refrain from soliciting employees, customers or suppliers of such previous employer or other party. The Advisor further
represents that his performance of all the terms of this Agreement and the performance of his duties as a consultant of the Company
do not and will not breach any agreement with any prior or current employer or other party to which the Advisor is a party (including
without limitation any nondisclosure or non-competition agreement), and that the Advisor will not disclose to the Company or induce
the Company to use any confidential or proprietary information or material belonging to any previous or current employer or others.

 

7.4. United States Government Obligations.
The Advisor acknowledges that the Company from time to time may have agreements with other persons or with the United States Government,
or agencies thereof, which impose obligations or restrictions on the Company regarding inventions made during the course of work
under such agreements or regarding the confidential nature of such work. The Advisor agrees to be bound by all such obligations
and restrictions which are made known to the Advisor and to take ail action necessary to discharge the obligations of the Company
under such agreements.

 

7.5. Stark Law. It is the intent of
the parties that terms and conditions of this agreement comply with certain federal and state laws, rules and regulations concerning
the delivery of health care services, including, without limitation, the Stark Law, the Fraud and Abuse Law, and the general proscription
on false claims in Medicare and Medicaid codified at 42 U.S.C.A. §1320a-7(a). Accordingly, the parties agree that the amount
of fees set in accordance with this agreement shall not be modified except on each anniversary of the Commencement Date as provided
in Paragraph 1; and shall not be premised on the volume or value of any patient, or to any hospital or medical facility owned or
operated by RPS or its affiliates. Nothing contained herein shall be interpreted as requiring EHC to refer or admit any patients
to any hospital or medical facility owned or operated by Advisors or its affiliates, or to obtain medical goods or services from
Advisors or its affiliates. In the event there is a change in the applicable federal or state statutes, rules, regulations, principles
or interpretations that reasonably may render any of the material terms of this Lease unlawful or unenforceable, including any
services rendered or compensation to be paid hereunder, or if the continuation of this agreement may reasonably render any other
relationship(s) amongst the parties hereto illegal, either party shall have the immediate right to initiate the renegotiation of
the affected Term or Terms of this agreement, upon notice to the other party, to remedy such condition. The parties shall thereafter
negotiate using their best efforts to restructure this agreement so as to make the same lawful, and to the extent possible, to
maintain the economic benefits to each party as contemplated hereunder. Should the parties be unable to renegotiate the Term or
Terms so affected so as to bring it/them into compliance with the statute, rule, regulation, principle or interpretation that rendered
it/them unlawful or unenforceable within fifteen (15) days of the date on which notice of a desired renegotiation is given, then
such disputes shall give rise to the parties’ rights to arbitration.

 

    	6

    	 

    

 

8. Independent Contractor Status. The
Advisor shall perform all services under this Agreement as an “independent contractor” and not as an employee or agent
of the Company. The Advisor is not authorized to assume or create any obligation or responsibility, express or implied, on behalf
of, or in the name of, the Company or to bind the Company in any manner.

 

9. Indemnification. With regard to the
services to be performed by the Advisor pursuant to the terms of this Agreement, the Advisor shall not be liable to the Company,
or to anyone who may claim any right due to his relationship with the Company, for any acts or omissions in the performance of
said services on the part of the Advisor or on the part of the agents or employees or contractors of the Advisor, except when said
acts or omissions of the Advisor or agents, employees, of contractors of the Advisor are due to their willful misconduct of gross
negligence. The company shall hold the Advisor and its agents, employees, or contractors (each an “indemnified person”)
free and harmless from any obligations, costs, claims, judgments, attorney fees and disbursements, and attachments arising from
or growing out of the services rendered to the Company pursuant to the terms of this Agreement or in any way connected with the
rendering of said services, except when the same shall arise solely due to the willful misconduct or gross negligence of the indemnified
person as finally judicially determined by a court of competent jurisdiction. The Company agrees that the indemnification and reimbursement
commitment set forth in this Agreement shall apply whether or not the indemnified person is a formal party to any such lawsuits
or other proceeding, that the indemnified person is entitled to retain separate counsel of its choice in connection with any of
the matter to which such indemnification relates and such indemnification shall survive any termination of this Agreement. The
company further agrees that it will not, without the prior written consent of the indemnified person, settle, compromise or consent
to the entry of any judgment in any pending or threatened claim in respect of which indemnification may be sought hereunder (whether
or not the indemnified person is an actual or potential party to such claim), if such settlement, compromise or consent includes
any injunctive relief against the indemnified person.

 

10. Notices. All notices required or
permitted under this Agreement shall be in writing and shall be deemed effective upon personal delivery or upon deposit in the
United States Post Office, by registered or certified mail, postage prepaid, addressed to the other party at the address shown
above, or at such other address or addresses as either party shall designate to the other in accordance with this Section 10.

 

11. Pronouns. Whenever the context may
require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular
forms of nouns and pronouns shall include the plural, and vice versa.

 

12. Entire Agreement. This Agreement
constitutes the entire agreement between the parties and supersedes all prior agreements and understandings, whether written or
oral, relating to the subject matter of this Agreement.

 

13. Amendment. This Agreement may be
amended or modified only by a written instrument executed by both the Company and the Advisor.

 

    	7

    	 

    

 

14. Governing Law. This Agreement shall
be construed, interpreted and enforced in accordance with the laws of the State of California.

 

15. Successors and Assigns. This Agreement
shall be binding upon, and inure to the benefit of, both parties and their respective successors and assigns, including any corporation
with which, or into which, the Company may be merged or which may succeed to its assets or business, provided, however, that the
obligations of the Advisor are personal and shall not be assigned by him.

 

16. Miscellaneous.

16.1. No delay or omission by the Company or
the Advisor in exercising any right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent
given by the Company or the Advisor on any one occasion shall be effective only in that instance and shall not be construed as
a bar or waiver of any right on any other occasion.

 

16.2. The captions of the sections of this
Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of
this Agreement.

 

16.3. In the event that any provision of this
Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions
shall in no way be affected or impaired thereby.

 

16.4. The Advisor represents that it has the
competence required to perform in a professional manner the services contemplated herein. The company understands and acknowledges
that the Advisor has made no express or implied warranties apart from this Agreement.

 

16.5. The Company agrees to cooperate with
the Advisor on all reasonable requests made by the Advisor including, without limitation, allowing the Advisor reasonable access
to the Company’s place of business, staff members, books and records to permit the Advisor to perform its services as fully
and economically as possible. The Advisor may not be held liable for non-performance where the Advisor is unable to perform, or
performance is delayed, due to circumstances beyond the Advisor’s control including those caused by the Company.

 

17. Notices. Payments, notices, or other
communications required by this Agreement shall be sufficiently made or given if mailed by certified mail, postage pre-paid, addressed
to the address stated below, or to the last address specified in writing by the intended recipient, or by commercial carrier (e.g.,
Airborne, Federal Express, etc.) when such carrier maintains certification of delivered mail.

 

    	8

    	 

    

 

	(a) If to Company:	 	
        eWellness Healthcare Corporation

        Douglas C. MacLellan, Chairman

        11825 Major Street

        Culver City, California 90230

 

IN WITNESS WHEREOF, the parties hereto have
executed this Agreement as of the day and year set forth above.

 

	eWELLNESS HEALTHCARE CORPORATION	 
	 	 
	
        Douglas C. MacLellan

        Chairman
	 
	 	 
	
        ADVISOR
	 
		 
	
        Akash Bajaj M.D., M.P.H.
	 

 

    	9ex10-1.htm

Exhibit 10.1

 

NON-EMPLOYEE DIRECTOR COMPENSATION

 

 

Cash compensation for non-employee directors is as follows: 

	 	 	 	 
	
Position
	 	
Annual Retainer
	 
	 	 	 	 	 
	
All Members (Base)
	 	$	25,000	 
	
Additional Retainers
	 	 	 	 
	
Board Chairman
	 	$	20,000	 
	
Board Vice Chairman
	 	$	5,000	 
	
Audit Committee Chairman
	 	$	15,000	 
	
Compensation Committee Chairman
	 	$	10,000	 
	
Nominating Committee Chairman
	 	$	--	 
	
Audit Committee Member (other than Chairman)
	 	$	5,000	 
	
Compensation Committee Member (other than Chairman)
	 	$	5,000	 
	
Nominating Committee Member (other than Chairman)
	 	$	--	 

 

Equity compensation for non-employee directors is as follows:

 

Annual Grants. Each year, immediately following Cardica, Inc.’s Annual Meeting of Stockholders, each non-employee director will automatically be granted an option to purchase 50,000 shares of the Company’s common stock. Each such option will vest monthly over the ensuing year.

 

Initial Grants. Automatically upon becoming a director, any new non-employee director shall be granted an option to purchase 75,000 shares of Cardica, Inc.’s common stock, vesting monthly over three years.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]